Eylward Susan 4

What Happened

• Susan Eylward, General Counsel and Corporate Secretary of Imunon, received 2,150 shares on 2026-07-17 as a stock grant in lieu of cash for part of her base salary (value: 2,150 × $1.83 = $3,935). She then sold the same 2,150 shares in an open-market transaction on 2026-07-20 for a weighted average price of $1.7816 per share (proceeds ≈ $3,830). The sequence (award then sale) is consistent with compensation-related shares being converted to cash.

Key Details

• Transactions:
  • 2026-07-17 — Award (A): 2,150 shares @ $1.83 (acquired) — $3,935 (footnote F1: stock granted in lieu of cash for portion of base salary).
  • 2026-07-20 — Sale (S): 2,150 shares @ weighted avg $1.7816 (prices ranged $1.76–$1.79) — proceeds ≈ $3,830 (footnote F2: breakout of per-price quantities available on request).
• Filing: Form 4 filed 2026-07-21 (Accession 0001437749-26-023948). The filing shows these transactions; it does not indicate tardiness.
• Shares owned after the transactions: not specified in the filing.
• Codes: A = award/grant, S = open-market sale.

Context

• This appears to be routine compensation-driven activity (shares granted in lieu of cash and then sold), not necessarily a personal directional bet on the stock. The dollar amounts are modest (~$3.8k), so this trade is small relative to typical institutional or director trades.